BREYANZI® MAKES COMPLETE AND
LASTING REMISSION POSSIBLE
RECLAIM TOMORROW: ACHIEVE PROLONGED RESULTS WITH A ONE-TIME INFUSION*
Explore the clinical trial results below or view the potential side effects.
COMPLETE REMISSION IS POSSIBLE AFTER 2 OR MORE PRIOR TREATMENTS
Who was in this study and what were the results?
A clinical study evaluated 114 adult patients with follicular lymphoma (FL) that had come back or stopped responding to treatment after 2 or more other types of treatment.
This is called overall response, which was seen in 90 out of 94 people and measures a decrease or disappearance of cancer in the body.
This is called complete response, which was seen in 69 out of 94 people. Complete response means there were no signs of cancer in the body, but it does not mean the cancer has been cured.
The rest of the people who responded (21 out of 94 people, or 22%) experienced a decrease of cancer in the body. This is called partial response.
RAPID REMISSION WAS SEEN WITH SOME PEOPLE EXPERIENCING COMPLETE OR PARTIAL RESPONSE AROUND 1 MONTH
In the clinical study, complete response was seen around 3 months (median) after infusion. This ranged from 0.6 months to 18 months.
Lasting remission is within reach:
This is called duration of response. Out of the 90 people who responded to treatment with Breyanzi, approximately 77% continued to respond after 18 months.
*The treatment process includes blood collection, CAR T cell creation, administration, and side-effect monitoring. No maintenance therapy for the lymphoma is needed after Breyanzi as long as you are responding to treatment.
These are the results experienced by people in the Breyanzi clinical studies. Your results may be different.
Learn more about Breyanzi for the treatment of R/R FL
Get to know this CAR T cell therapy in detail, including the clinical trial results, safety information, and treatment process.
R/R, relapsed or refractory.